EPIGENOMIC PROGRAMMING
Dead / Abandoned — Abandoned — failure to respond (as of 08 May 2023)
What this means for you
This application is over — abandoned 21 Apr 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97331015
- Mark type
- Stylized text
- Filed
- 25 Mar 2022
- Abandoned
- 21 Apr 2023
- Attorney of record
- Patrick J. Concannon
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical agents affecting DNA structure and/or epigenomic state by targeting DNA structure to treat various diseases; Pharmaceutical agents affecting DNA structure and/or epigenomic state by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease, CNS disorders
Owner
- Omega Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 08 May 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 08 May 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
- 08 May 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 20 Jan 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 20 Jan 2023 — NON-FINAL ACTION E-MAILED
- 20 Jan 2023 — NON-FINAL ACTION WRITTEN
- 09 Jan 2023 — ASSIGNED TO EXAMINER
- 30 Mar 2022 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 29 Mar 2022 — NEW APPLICATION ENTERED